The increase in rat ventricular automaticity induced by salbutamol is mediated through β1- but not β2-adrenoceptors: Role of phosphodiesterases

Life Sciences

Volumn 88, Issue 25-26, 2011, Pages 1095-1101

  Gonzalez Muñoz, Carmen ^a   Fuente, Teodomiro ^a   Medin Aguerre, Santiago ^a   Hernández Cascales, Jesús ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

adrenoceptors; Phosphodiesterases; Theophylline; Ventricular automaticity

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CILOSTAMIDE; CYCLIC AMP; MILRINONE; PHOSPHODIESTERASE; ROLIPRAM; SALBUTAMOL; THEOPHYLLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART AUTOMATICITY; HEART RIGHT VENTRICLE; MALE; NONHUMAN; RAT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANIMALS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART VENTRICLES; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; THEOPHYLLINE; VENTRICULAR FUNCTION;

RATTUS;

EID: 79958073008     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.04.015     Document Type: Conference Paper

References (50)

1. Anderson GP. Current issues with β2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. Clin Rev Allerg Immu 2006;31:119-30. (Pubitemid 44804943)
2. Astschuld RA, Billman GE. β2-Adrenoceptors and ventricular fibrillation. Pharmacol Therapeut 2000;88:1-14.
3. Baker JJ. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Brit J Pharmacol 2005;144:317-22.
4. Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Brit J Pharmacol 2009;157:892-906.
5. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med 2003;167:813-8. (Pubitemid 36801766)
6. Bassiakou E, Xanthos T, Koudouna E, Goulas S, Prapa V, Papadimitriou D, et al. Atenolol in combination with epinephrine improves the inicial outcome of cardiopulmonary resuscitation in a swine model of ventricular fibrillation. Am J Emerg Med 2008;26:578-84. (Pubitemid 351755010)
7. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520. (Pubitemid 44394910)
8. Bethke T, Meyer W, Schmitz W, Scholz SH, Wenzlaff H, Armah BI, et al. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium. J Cardiovasc Pharm 1993;21:847-55. (Pubitemid 23160670)
9. 2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997;96:1914-22.
10. Brodde OE, Bruck H, Leineweber K. Cardiac ardenoceptors: physiological and pathological relevance. J Pharm Sci 2006;100:323-37. (Pubitemid 44609527)
11. Calabrò MP, DeLuca FL, Gitto E, Oreto G. Salbutamol-induced narrow QRS tachycardia. J Cardiovasc Electr 2006;17:792-3.
12. Cammarata G, Weil MH, Sun S, Tang W, Wang J, Huang L. Beta1-adrenergic blockade during cardiopulmonary resuscitation improves survival. Crit Care Med 2004;32:S440-3.
13. 2-adrenoceptors in sheep Purkinje fibers. J Mol Cell Cardiol 1990;22:859-70.
14. Charpentier F, Rosen MR. β-Adrenergic regulation of action potentials and automaticity in young and adult canine Purkinje fibers. Am J Phys 1994;266:H2310-9.
15. Chorostowska-Wynimko J, Kus J, Skopinska-Rozewska E. Theophylline inhibits free oxygen radicals production by human monocytes via phosphodiesterase inhibition. J Physiol Pharmacol 2007;58(suppl. 5):95-103. (Pubitemid 351346658)
16. Chung KF. Phosphodiesterase inhibitors in airway disease. Eur J Pharmacol 2006;533:110-7.
17. Cui Y, Shen YT, Kalthof B, Iwase M, Sata N, Uechi M, et al. Identification and functional role of beta-adrenergic receptor subtypes in primate and rodent: in vivo versus isolated myocytes. J Mol Cell Cardiol 1996;28:1307-17. (Pubitemid 26174422)
18. Dent G, Giembycz MA, Rabe KF, Wolf B, Barnes PJ, Magnussen H. Theophylline suppress human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am J Respir Cell Mol Biol 1994;10:565-72.
19. 2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ Res 2008;102:1389-97.
20. DiFrancesco D. The role of funny current in pacemaker activity. Circ Res 2010;106:434-46.
21. Elers J, Pedersen L, Henninge J, Lund TK, Hemmersbach P, Dalhoff K, et al. Blood and urinary concentrations of salbutamol in asthmatic subjects. Med Sci Sport Exer 2010;42:244-9.
22. Finn AF, Thompson CM, Banov CH, O'Connor BK, Case CL. Beta-2 agonist induced ventricular arrhytmias secondary to hyperexcitable conduction system in the absence of a long QT syndrome. Ann Allerg Asthma Im 1997;78:230-2. (Pubitemid 27082233)
23. 2-agonists in rat heart cell culture. Brit J Pharmacol 1983;78:717-23.
24. Gonzalez-Muñoz C, Fuente T, Hernández-Cascales J. Phosphodiesterases inhibition unmask a positive inotropic effect mediated by beta2-adrenoceptors in rat ventricular myocardium. Eur J Pharmacol 2009;607:151-5.
25. Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, et al. The safety and effects of the beta-blocker nadolol in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008;21:134-41.
26. Hatzemann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al. The preclinical pharmacology of roflumilast - a selective oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010;23:235-56.
27. Hernandez J, Ribeiro JA. Excitatory actions of adenosine on ventricular automaticity. Trends Pharmacol Sci 1996;17:141-4. (Pubitemid 26122415)
28. 1-adrenoceptors on cardiac automaticity in the isolated right ventricle of the rat. Brit J Pharmacol 1994;111:1316-20.
29. Hernández J, Laorden ML, Ruiz F, Ribeiro JA. Effects of adenosine and its analogues on ventricular automaticity induced by a local injury: role of catecholamines and of cyclic AMP. Arch Int Pharmacodyn Ther 1989;297:49-59. (Pubitemid 19066348)
30. Hoppe UC, Jansen E, Südkamp M, Beuckelmann DJ. Hyperpolarization- activated current in ventricular myocytes from normal and failing human heart. Circulation 1998;97:55-65. (Pubitemid 28036155)
31. Huerta C, Lanes SF, Garcia-Rodriguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005;16:360-6. (Pubitemid 40586712)
32. Janson C. Plasma levels and effects of salbutamol after inhaled or i.v. administration in stable asthma. Eur Respir J 1991;4:544-50.
33. Juan-Fita MJ, Vargas ML, Hernández J. Comparative actions of diazepam and other phosphodiesterase inhibitors on the effects of noradrenaline in rat myocardium. Pharmacol Toxicol 2003;93:23-8. (Pubitemid 36819370)
34. Juan-Fita MJ, Vargas ML, Hernández J. The phosphodiesterase 3 inhibitor cilostamide enhances inotropic responses to glucagon but not to dobutamine in rat ventricular myocardium. Eur J Pharmacol 2005;512:207-13. (Pubitemid 40544355)
35. 2- adrenoceptor binding and functional response in right and left atria of rat heart. N S Arch Pharmacol 1985;330:193-202.
36. Katano Y, Endoh M. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone and isobutylmethylxantine. J Cardiovasc Pharm 1992;20:715-22.
37. Koumi S, Backer CL, Arentzen CE, Sato R. β-Adrenergic modulation of the inwardly rectifying potassium channel in isolated human ventricular myocytes. J Clin Invest 1995;96:2870-81.
38. Lemaitre RN, Siscovick DS, Psaty BM, Pearce RM, Raghunathan TE, Whitsel EA, et al. Inhaled beta-2 adrenergic reseptor agonists and primary cardiac arrest. Am J Med 2002;113:711-6. (Pubitemid 36044695)
39. Leroy J, Abi-Gerges A, Nokolaev VO, Richter W, Lechene P, Mazet JL, et al. Spatiotemporal dynamics of β-adrenergic cAMP signals and L-type Ca+2 channel regulation in adult rat ventricular myocytes: role of phosphodiesterases. Circ Res 2008;102:1091-100. (Pubitemid 351667863)
40. Lipworth BJ, Williamson PA. β blockers for asthma: a double-edged sword. Lancet 2009;373:104-5.
41. Mangoni ME, Nargeot J. Genesis and regulation of heart automaticity. Physiol Rev 2008;88:919-82.
42. Nicholson CD, Challiss RAJ, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 1991;12:19-27.
43. 2-adrenergic receptor-mediated signalling. Circ Res 2006;99:1084-91.
44. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP. Current use of beta blockers in patient with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009;103:295-300.
45. Rochais F, Abi-Gerges A, Horner K, Lefebvre F, Cooper DM, Conti M, et al. A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocardium. Circ Res 2006;98:1081-8.
46. Schäfers RF, Adler S, Dault A, Zeitler G, Vogelsang M, Zerkowski HR, et al. Positive inotropic effects of the beta2-adrenoceptor agonist terbutaline in the human heart. J Am Coll Cardiol 1994;23:1224-33.
47. Suissa S, Hemmelgam B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996;154:1598-602. (Pubitemid 26424921)
48. Tandeter H, Kobal S, Katz A. Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature. Clin Cardiol 2010;33:E116-20.
49. Xanthos T, Bassiakou E, Koudouna E, Rokas G, Goulas S, Dontas I, et al. Combination pharmacotherapy in the treatment of experimental cardiac arrest. Am J Emerg Med 2009;27:651-9.
50. Xiao RP, Ji X, Lakatta EG. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 1995;47:322-9.